![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vol. 305, Issue 1, 151-158, April 2003
Department of Pharmaceutics, Victorian College of Pharmacy, Monash
University, Parkville, Victoria, Australia (B.M.J., W.N.C., C.J.H.P.),
and Department of Pharmaceutical Chemistry, the University of Kansas,
Lawrence, Kansas (W.C., R.T.B.)
P-glycoprotein (P-gp)-mediated drug efflux from the apical membrane of
enterocytes is believed to modulate intestinal cytochrome P450 3A
(CYP3A) metabolism by altering substrate access to the CYP3A enzyme.
This interplay between P-gp and CYP3A was investigated in a rat in situ
model of intestinal permeation, where a recirculating luminal perfusion
of the jejunum was coupled with mesenteric vein blood collection to
simultaneously monitor the uptake, transport, and metabolism of the
P-gp and CYP3A substrate, verapamil. Transport of intact verapamil into
the venous blood was increased by 160, 84, and 160%, and the
intestinal extraction ratio on passage across the jejunum was reduced
by 15, 24, and 97% by inhibitors of P-gp [PSC833
([3'-keto-Me-Bmt1]-[Val2]-cyclosporin)],
CYP3A (midazolam), or P-gp and CYP3A (ketoconazole), respectively, when
present in the luminal perfusate and compared with control experiments.
Compartmental kinetic analysis of the data revealed that inhibition of
P-gp did not affect the rate constant describing verapamil metabolism
but, rather, increased the intestinal uptake of verapamil and
stimulated a disproportionate increase in verapamil transport into the
venous blood. The increase in verapamil transport, in the absence of
changes to metabolism, reduced the intestinal extraction ratio. This
finding may be explained by saturation of intracellular verapamil
binding sites within the intestinal tissue in response to increased
verapamil uptake resulting from P-gp inhibition. The current findings
confirm previous in vitro and theoretical approaches which suggest that
P-gp can modulate the extent of intestinal extraction of P-gp/CYP3A substrates.
This article has been cited by other articles:
![]() |
H. H. Usansky, P. Hu, and P. J. Sinko Differential Roles of P-Glycoprotein, Multidrug Resistance-Associated Protein 2, and CYP3A on Saquinavir Oral Absorption in Sprague-Dawley Rats Drug Metab. Dispos., May 1, 2008; 36(5): 863 - 869. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Cao, X. Chen, J. Liang, X.-Q. Yu, A.-L. Xu, E. Chan, D. Wei, M. Huang, J.-Y. Wen, X.-Y. Yu, et al. Role of P-glycoprotein in the Intestinal Absorption of Glabridin, an Active Flavonoid from the Root of Glycyrrhiza glabra Drug Metab. Dispos., April 1, 2007; 35(4): 539 - 553. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zhang, M. Huang, S. Guan, H.-C. Bi, Y. Pan, W. Duan, S. Y. Chan, X. Chen, Y.-H. Hong, J.-S. Bian, et al. A Mechanistic Study of the Intestinal Absorption of Cryptotanshinone, the Major Active Constituent of Salvia miltiorrhiza J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1285 - 1294. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Matheny, R. Y. Ali, X. Yang, and G. M. Pollack EFFECT OF PROTOTYPICAL INDUCING AGENTS ON P-GLYCOPROTEIN AND CYP3A EXPRESSION IN MOUSE TISSUES Drug Metab. Dispos., September 1, 2004; 32(9): 1008 - 1014. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Tam, H. Sun, and K. S. Pang INFLUENCE OF P-GLYCOPROTEIN, TRANSFER CLEARANCES, AND DRUG BINDING ON INTESTINAL METABOLISM IN CACO-2 CELL MONOLAYERS OR MEMBRANE PREPARATIONS: A THEORETICAL ANALYSIS Drug Metab. Dispos., October 1, 2003; 31(10): 1214 - 1226. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. M. Johnson, W. N. Charman, and C. J. H. Porter APPLICATION OF COMPARTMENTAL MODELING TO AN EXAMINATION OF IN VITRO INTESTINAL PERMEABILITY DATA: ASSESSING THE IMPACT OF TISSUE UPTAKE, P-GLYCOPROTEIN, AND CYP3A Drug Metab. Dispos., September 1, 2003; 31(9): 1151 - 1160. [Abstract] [Full Text] [PDF] |
||||